OMERHealthcare · BiotechnologyThe 3 Wall Street analysts covering Omeros Corp. hold a median 12-month price target of $33 — +92.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 15 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Omeros Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (98): Analysts have, on balance, been raising their forecasts.
Volatility (8): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on OMER, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +92.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 June 2026 | HC Wainwright & Co. | Maintains | Buy | $40 → $33 |
| 10 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 21 Apr 2026 | D. Boral Capital | Maintains | Buy | — |
| 27 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 8 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 1 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 14 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 16 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Oct 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Oct 2025 | Needham | Reiterates | Hold | — |
| 15 Oct 2025 | WBB Securities | Reiterates | Strong Buy | — |
| 3 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | Needham | Reiterates | Hold | — |
| 25 July 2025 | D. Boral Capital | Maintains | Buy | — |
| 30 June 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OMER appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 7% of US stocks
Cheaper than 98% of US stocks
Cheaper than 89% of US stocks
Higher than 98% of US stocks
Higher than 46% of US stocks
Higher than 99% of US stocks
Higher than 49% of US stocks
Higher than 20% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Omeros Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Omeros stock surged to a five-year high Thursday after the company reported strong second-quarter results for its new treatment for transplant complications.
Why it matters — A OMER watcher would care because the company's stock reached a five-year high on the back of strong quarterly results for its new transplant-complication treatment, signalling notable commercial progress.
Seeking Alpha published the transcript of Omeros Corporation's second-quarter 2026 earnings call. The transcript covers the company's Q2 2026 earnings discussion.
Why it matters — OMER watchers would care because the earnings call transcript provides insight into the company's quarterly financial performance and management commentary.
Omeros reported $28.5 million in second-quarter net sales for its newly launched TA-TMA treatment YARTEMLEA. The company also generated positive operating cash flow and reduced its convertible debt after the quarter ended.
Why it matters — An OMER watcher would care because the early sales performance of YARTEMLEA, combined with positive cash flow and debt reduction, signals a potentially favorable trajectory for the company's newest product.
Omeros reported Q2 earnings of $0.02 per share, surpassing the Zacks Consensus Estimate which had projected a loss of $0.27 per share. This compares favorably to a loss of $0.53 per share in the same quarter last year.
Why it matters — The earnings beat marks a significant turnaround from both analyst expectations and the company's year-ago performance, indicating potentially improving financial health for OMER.
Omeros Corporation announced its financial results for the second quarter ended June 30, 2026, along with recent highlights and developments. The company reported that YARTEMLEA, its approved treatment for stem cell transplant-associated thrombotic microangiopathy (TA-TMA), generated gross revenues of $32.2 million in the second quarter.
Why it matters — The revenue figures for YARTEMLEA provide OMER watchers with an early indicator of the commercial performance of the company's first approved product.
The 3 Wall Street analysts covering Omeros Corp. have a median 12-month price target of $33, with estimates ranging from $33 to $33. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 3 analysts covering Omeros Corp., 1 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Omeros Corp. 90 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Omeros Corp. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (98 of 100).
No one can know that. What the data says: the median 12-month target from 3 analysts implies +92.0% from the last close, and Ticker Nerd's factor model ranks Omeros Corp. 90 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Omeros Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OMER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $33 to $33 over the next 12 months.
Omeros Corp. returned +317.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It targets large-market opportunities as well as orphan indications, particularly in areas such as inflammation, coagulopathies, disorders of the central nervous system, and complement-mediated diseases including immunologic disorders, cancers, and addictive and compulsive disorders.
The most recent item we track (Investors Business Daily, 13 Aug 2026): "This Biotech Stock Just Gapped Up To A Five-Year High; Here's Why". Omeros stock surged to a five-year high Thursday after the company reported strong second-quarter results for its new treatment for transplant complications.
Omeros Corporation is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and protein therapeutics. It targets large-market opportunities as well as orphan indications, particularly in areas such as inflammation, coagulopathies, disorders of the central nervous system, and complement-mediated diseases including immunologic disorders, cancers, and addictive and compulsive disorders. Notable product candidates include narsoplimab (OMS721), a monoclonal antibody inhibiting mannan-binding lectin-associated serine protease-2 to address the lectin pathway of complement, used for conditions like hematopoietic stem-cell transplant-associated thrombotic microangiopathy. The company also advances other pipeline assets like OMS1029 and MASP-3 inhibitors such as zaltenibart for rare diseases including paroxysmal nocturnal hemoglobinuria. Omeros Corporation operates within the health technology sector, emphasizing innovative treatments for unmet medical needs. Founded in 1994 and headquartered in Seattle, Washington, it plays a key role in advancing biopharmaceutical solutions for complex therapeutic challenges.
CEO Dr. Gregory A. Demopulos M.D. · 175 employees · United States · https://www.omeros.com